標(biāo)題: Titlebook: Gene Transfer in the Cardiovascular System; Experimental Approac Keith L. March Book 1997 Springer Science+Business Media New York 1997 DNA [打印本頁] 作者: 貪吃的人 時(shí)間: 2025-3-21 16:42
書目名稱Gene Transfer in the Cardiovascular System影響因子(影響力)
書目名稱Gene Transfer in the Cardiovascular System影響因子(影響力)學(xué)科排名
書目名稱Gene Transfer in the Cardiovascular System網(wǎng)絡(luò)公開度
書目名稱Gene Transfer in the Cardiovascular System網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Gene Transfer in the Cardiovascular System被引頻次
書目名稱Gene Transfer in the Cardiovascular System被引頻次學(xué)科排名
書目名稱Gene Transfer in the Cardiovascular System年度引用
書目名稱Gene Transfer in the Cardiovascular System年度引用學(xué)科排名
書目名稱Gene Transfer in the Cardiovascular System讀者反饋
書目名稱Gene Transfer in the Cardiovascular System讀者反饋學(xué)科排名
作者: LATE 時(shí)間: 2025-3-21 23:29
Adenoviruses (Part II): Improvement of Adenoviral Vectors for Human Gene Therapy: E1 and E4 Deleted . Boulanger (Montpellier, France) for providing us with antibodies raised against the adenoviral fiber protein, Dr. T. Shenk (Princeton, New Jersey, U.S.A.) and Dr. P. Hearing (Stony Brook, New York, U.S.A.) for their kind gift of antibodies raised against the E4 gene products. We thank A. Gillardea作者: 飛鏢 時(shí)間: 2025-3-22 02:20
Adeno-Associated Virus and Other New DNA Virus VectorsThis feature may expand their utility in post-mitotic cells such as cardiac myocytes. Among DNA virus vectors, adenovirus (Ad) and adeno-associated virus type 2 (AAV) have been most thoroughly studied. The natural history of human AAV infection has not been studied as completely as Ad infection, but作者: 波動 時(shí)間: 2025-3-22 07:59
Plasmid and Other Non-Viral Vectorsheim Biochemicals and Kurt Naujoks from Boehringer Mannheim Therapeutics for the critical reading of this manuscript and helpful discussions. In addition, I also thank the following individuals for providing me with information for this chapter: Uwe Michaelis from Boehringer Mannheim Therapeutics, M作者: 蚊子 時(shí)間: 2025-3-22 12:27 作者: 后天習(xí)得 時(shí)間: 2025-3-22 14:33 作者: 后天習(xí)得 時(shí)間: 2025-3-22 18:55
Catheter Based Local Drug and Gene Deliveryve growth in the number of procedures performed. Until just recently, however, there has been little advancement in reducing the frequency of restenosis and the incidence of angiographic restenosis, broadly defined as the partial or total reocclusion of the artery to 50% of the original lumen, has r作者: Ischemic-Stroke 時(shí)間: 2025-3-22 21:21 作者: periodontitis 時(shí)間: 2025-3-23 05:23 作者: cavity 時(shí)間: 2025-3-23 07:18
Viral Vector-Based Vascular Gene Delivery: Basic Studies and Therapeutic Applicationsolved from initial studies demonstrating the feasibility of cell mediated and direct gene transfer into blood vessels to studies examining the pathophysiology of vascular diseases and therapeutic applications. Despite these advances, technical challenges persist related to optimization of vectors, e作者: 啪心兒跳動 時(shí)間: 2025-3-23 13:13 作者: Morphine 時(shí)間: 2025-3-23 17:55 作者: PATHY 時(shí)間: 2025-3-23 21:00 作者: 徹底明白 時(shí)間: 2025-3-23 22:58 作者: 字形刻痕 時(shí)間: 2025-3-24 05:28 作者: Microaneurysm 時(shí)間: 2025-3-24 09:35
Fibrinogen and its Degradation Products clinics throughout the world has led to conceptualization and evaluation of strategies for gene therapy for a number of genetic and acquired disorders. At the time of this writing, 136 clinical trials have been approved by the National Institutes of Health (NIH) Recombinant DNA Activities Committee作者: 陰險(xiǎn) 時(shí)間: 2025-3-24 14:44
Psychometric Principles and Issues. Boulanger (Montpellier, France) for providing us with antibodies raised against the adenoviral fiber protein, Dr. T. Shenk (Princeton, New Jersey, U.S.A.) and Dr. P. Hearing (Stony Brook, New York, U.S.A.) for their kind gift of antibodies raised against the E4 gene products. We thank A. Gillardea作者: GLUT 時(shí)間: 2025-3-24 18:54
Parent and Teacher Rating ScalesThis feature may expand their utility in post-mitotic cells such as cardiac myocytes. Among DNA virus vectors, adenovirus (Ad) and adeno-associated virus type 2 (AAV) have been most thoroughly studied. The natural history of human AAV infection has not been studied as completely as Ad infection, but作者: Neuropeptides 時(shí)間: 2025-3-24 19:27 作者: 啞劇 時(shí)間: 2025-3-25 01:57 作者: Visual-Acuity 時(shí)間: 2025-3-25 05:10 作者: amenity 時(shí)間: 2025-3-25 09:12 作者: 意外的成功 時(shí)間: 2025-3-25 14:10 作者: 辯論的終結(jié) 時(shí)間: 2025-3-25 17:41 作者: 黃油沒有 時(shí)間: 2025-3-25 22:13 作者: CUR 時(shí)間: 2025-3-26 01:22
Retinal Pigment Epithelial Lesions,with the blood, and (2) the large vessel arterial and venous circulation communicating between the heart and capillary beds. Each of these regions of the vascular system presents unique opportunities for both vascular biologists and gene therapists for the study and treatment of disorders that are e作者: comely 時(shí)間: 2025-3-26 06:14
Abdulrahman H. Algaeed,Igor Kozakany of their functions in normal and diseased states have been defined. Vascular smooth muscle cells are the principal cellular component of large arteries and veins, and they maintain the physical state of the vasculature because of their contractile and matrixsynthesizing properties. They are also作者: 尊嚴(yán) 時(shí)間: 2025-3-26 11:52
Tractional Retinal Degenerations,hyperplasia, considered a result of uncontrolled medial smooth muscle cell proliferation [1–5]. Studies in the rat carotid artery injury model has been the basis of this paradigm, having been documented in many studies [6, 7]. Therapies aimed at inhibiting proliferation have been quite successful in作者: Entirety 時(shí)間: 2025-3-26 15:23
Abdulkadir Goksel,Khanh Ngoc Tranmulations of angiogenic growth factors to expedite and/or augment collateral artery development in animal models of myocardial and hindlimb ischemia — “therapeutic angiogenesis” — has now been well established. These studies have suggested that two angiogenic growth factors in particular, basic fibr作者: Protein 時(shí)間: 2025-3-26 18:51
https://doi.org/10.1007/978-3-319-07371-2rotein may be achieved with a single engraftment of recombinant cells. Grafted cells may create high local concentrations of an agent while secreting low absolute levels, possibly increasing desired effects while reducing complications associated with systemic delivery. This method of delivery is ex作者: habitat 時(shí)間: 2025-3-27 00:17 作者: 摻假 時(shí)間: 2025-3-27 04:15
Introduction to Heart Rate Variabilityes, discuss the nature and theoretical basis of this approach, and examine its in vivo application. We will primarily focus on application of antisense techniques to vascular smooth muscle cell studies, but other areas of applications will be mentioned as well.作者: GLOSS 時(shí)間: 2025-3-27 06:21 作者: transdermal 時(shí)間: 2025-3-27 12:13
Retinal Pigment Epithelial Lesions,with the blood, and (2) the large vessel arterial and venous circulation communicating between the heart and capillary beds. Each of these regions of the vascular system presents unique opportunities for both vascular biologists and gene therapists for the study and treatment of disorders that are either vascular or nonvascular in origin.作者: LANCE 時(shí)間: 2025-3-27 17:33
Endogenous Expression Modification: Antisense Approacheses, discuss the nature and theoretical basis of this approach, and examine its in vivo application. We will primarily focus on application of antisense techniques to vascular smooth muscle cell studies, but other areas of applications will be mentioned as well.作者: Granular 時(shí)間: 2025-3-27 19:00
Targeted and Sustained-Release Delivery Concepts in Gene Therapy that could potentially be employed to address some of the deficiencies of current delivery vehicles employed in gene therapy. In particular, approaches that may provide for specific targeting or the sustained release of therapeutically administered genetic material are discussed.作者: Diskectomy 時(shí)間: 2025-3-27 22:56
Cell-Based Vascular Gene Delivery: Endothelial Cells as Carrierswith the blood, and (2) the large vessel arterial and venous circulation communicating between the heart and capillary beds. Each of these regions of the vascular system presents unique opportunities for both vascular biologists and gene therapists for the study and treatment of disorders that are either vascular or nonvascular in origin.作者: moribund 時(shí)間: 2025-3-28 04:04
978-1-4613-7881-5Springer Science+Business Media New York 1997作者: Myelin 時(shí)間: 2025-3-28 07:16 作者: 小歌劇 時(shí)間: 2025-3-28 11:52
Catheter Based Local Drug and Gene Deliverys surgery. Therefore, recognition by both clinical cardiologists and vascular biologists that restenosis is a major clinical problem has lead to the evaluation of local drug or gene delivery as a therapeutic approach. Restenosis appears to be particularly well-suited for site-specific treatment as i作者: 送秋波 時(shí)間: 2025-3-28 18:10
Fluid Dynamics of Catheter Delivery: Effects on Delivery Efficiency and Localizational delivery in the coronary arteries may be useful for therapy of restenosis, in situ thrombosis, stent thrombosis, prevention of atherosclerosis, modification of coronary artery spasm, induction of angiogenesis and other applications as well. Nevertheless, very few published data are available rega作者: acclimate 時(shí)間: 2025-3-28 19:55 作者: ORBIT 時(shí)間: 2025-3-28 23:22 作者: 上下連貫 時(shí)間: 2025-3-29 04:43
Normal Spine: X-ray and CT Anatomys surgery. Therefore, recognition by both clinical cardiologists and vascular biologists that restenosis is a major clinical problem has lead to the evaluation of local drug or gene delivery as a therapeutic approach. Restenosis appears to be particularly well-suited for site-specific treatment as i作者: 背帶 時(shí)間: 2025-3-29 09:29
Jennifer Saunders,Barbara Hungerfordal delivery in the coronary arteries may be useful for therapy of restenosis, in situ thrombosis, stent thrombosis, prevention of atherosclerosis, modification of coronary artery spasm, induction of angiogenesis and other applications as well. Nevertheless, very few published data are available rega作者: Assignment 時(shí)間: 2025-3-29 14:06 作者: Concomitant 時(shí)間: 2025-3-29 17:53
https://doi.org/10.1007/978-3-319-07371-2nant molecules to the brain, thymus, and hematopoietic system have appeared [reviewed in 2–5]. Ex-vivo gene therapy has also been used to treat a patient with familial hypercholesterolaemia. In this case, autologous hepatocytes were used to target expression of a recombinant LDL receptor, resulting 作者: miracle 時(shí)間: 2025-3-29 21:36
0166-9842 lop simpler delivery systems consisting of a plasmid combined with delivery agents. Viral-based systems are very successful for gene delivery, but despite their978-1-4613-7881-5978-1-4615-6277-1Series ISSN 0166-9842 作者: 疏遠(yuǎn)天際 時(shí)間: 2025-3-30 00:19
Book 1997brings together researchers interested in this field [1]. Assembly of an artificial virus is very complex; other research groups aim to develop simpler delivery systems consisting of a plasmid combined with delivery agents. Viral-based systems are very successful for gene delivery, but despite their作者: 打谷工具 時(shí)間: 2025-3-30 06:49 作者: filial 時(shí)間: 2025-3-30 10:41
0166-9842 cells resulting in the synthesis of the foreign protein For gene therapy, a tmnsferred therapeutic gene must be expressed at a level beneficial for the patient. This chapter provides an introductory overview of the rapidly evolving field of non-viral approaches for gene delivery to rnarnrnalian cel作者: MURKY 時(shí)間: 2025-3-30 13:35
Fibrinogen and its Degradation Productss. At the time of this writing, 136 clinical trials have been approved by the National Institutes of Health (NIH) Recombinant DNA Activities Committee (RAC) and more than 600 individuals have received transferred genes [1]. It is remarkable to note that the gene-enzyme basis of disease was first hypothesized by Garrod only 86 years ago.作者: PLAYS 時(shí)間: 2025-3-30 17:51 作者: Irksome 時(shí)間: 2025-3-30 21:09
https://doi.org/10.1007/978-3-030-35695-8ary Dasovich-Moody and Volker Kuenemund from Boehringer Mannheim Biochemicals, Xiao Chen from Progenitor, Inc., Mark Gessler from GeneMedicine Inc., Linda Hull from Genetronics, Inc., R. Douglas Hulse from RGene Therapeutics, Inc., Yuhong Xu from University of California, San Francisco and Robert Zaugg from Vical, Inc.
